Skip to main navigation menu Skip to main content Skip to site footer

Research Article

Vol. 3 No. 1 (1997)

Response of Very Premature Infants with Bronchopulmonary Dysplasia to Inhaled Salbutamol

  • Ha-Nam P. Nguyen
  • Dominic Fitzgerald, M.B.B.S., Ph.D., F.R.A.C.P.
  • Michael G. Davis, M.Sc., M.B.Ch.B., F.R.C.P.C., F.R.A.C.P.
DOI
https://doi.org/10.26443/mjm.v3i1.473
Submitted
November 1, 2020
Published
2020-12-01

Abstract

Bronchopulmonary Dysplasia (BPD) is the most common chronic respiratory disease found in premature infants following prolonged supplemental oxygen and mechanical ventilation. Although salbutamol, a selective ß2 agonist, is known to relax the hypertrophied smooth muscles around the small airways in adults, earlier literature has suggested that neonates did not have enough peribronchial smooth muscle for constriction and thus lacked a bronchodilatory response to ß2 agonists. The present study was designed to determine whether infants of less than 32 weeks gestational age with elevated lung resistance were responsive to salbutamol. Nineteen premature infants (mean gestational age 26.0 +/- 2.1 weeks and mean birth weight 851.3 +/- 244.4 g) were recruited for the study. Immediately before and 30 minutes after the commencement of nebulized salbutamol administration, a minimum of 15 breaths were measured and analyzed for each patient. From this breath-by-breath analysis, the lung mechanics and Work of Breathing (WOB) were calculated. Results were then compared by paired t-tests. The use of salbutamol resulted in a significant improvement in airway resistance (p = 0.008) and tendency for impedance reduction. These results indicate that very premature infants (< 32 weeks) with BPD respond favorably to bronchodilators. Although the mechanism of action remains to be elucidated, salbutamol most probably achieves its effects through the relaxation of the hypertrophied peribronchial smooth muscle. Early intervention to relieve airway obstruction may promote early weaning from mechanical ventilation and diminish both duration and severity of BPD.

References

  1. Northway, WH Jr., Rosan RC, Porter DY. Pulmonary disease following respiratory therapy of hyaline disease: bronchopulmonary dysplasia. New England Journal of Medicine 276(7): 357-368; 1967.
  2. Farrell PM, Palta M. Bronchopulmonary Dysplasia: Clinical Presentation and Pathogenesis. In: Report of the Ninetieth Ross Conference: Bronchopulmonary Dysplasia and Related Chronic Respiratory Disorders. Ohio: Ross Laboratories; 1986: 1-6.
  3. Fanburg BL, Deneke SM, Lee S, et al. Bronchopulmonary Dysplasia: Mediators of Lung Injury in Oxygen Toxicity. In: Report of the Ninetieth Ross Conference: Bronchopulmonary Dysplasia and Related Chronic Respiratory Disorders. Ohio: Ross Laboratories; 1986: 16-23.
  4. Groneck P, Gotze-Speer B, Oppermann M, et al. Association of Pulmonary Inflammation and Increased Microvascular Permeability During the Development of Bronchopulmonary Dysplasia: A Sequential Analysis of Inflammatory Mediators in Respiratory Fluids of High-Risk Preterm Neonates. Pediatrics 93(5): 712-718; 1994.
  5. Wood BP. The Newborn Chest. In: The Radiologic Clinics of North America - The Pediatric Chest. Philadelphia: W.B. Saunders Co.; 1993: 667 - 676.
  6. Bohin S, Field DJ. The epidemiology of neonatal respiratory disease. Early Human Development. 37(2): 73-90; 1994.
  7. Abman SH, Groothius JR. Pathophysiology and treatment of bronchopulmonary dysplasia. Pediatric Clinics of North America 41(2): 277-315; 1994.
  8. Vohr BR, Bell EF, Oh W. Infants with bronchopulmonary dysplasia: growth pattern and neurologic and developmental outcome. American Journal of Diseases of Children 136(5): 443-447; 1982.
  9. Northway WH, Moss RB, Carlisle KB, et al. Late pulmonary sequelae of bronchopulmonary dysplasia. New England Journal of Medicine 323(26): 1793-9; 1990.
  10. Cloutier MM. Nebulized Steroid Therapy in Bronchopulmonary Dysplasia. Pediatric Pulmonology 15(2): 111-116; 1993.
  11. Blanchard PW, Brown TM, Coates AL. Pharmacotherapy in bronchopulmonary dysplasia. Clinics in Perinatology 14(4): 881-910; 1987.
  12. Kao LC, Warburton D, Sargent CW, et al. Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia. Journal of Pediatrics 103(4): 624-629; 1983.
  13. Alpert BE, Allen JL, Schidlow DV. Bronchopulmonary Dysplasia. In: Hilman BC, ed. Pediatric Respiratory Disease - Diagnosis and Treatment. Philadelphia: W.B. Suanders Co.; 1993: 440-457.
  14. Gomez-Del Rio M, Gerhardt T, Herhe Disease, et al. Effect of a Beta-agonist Nebulization on Lung Function in Neonates with Increased Pulmonary Resistance. Pediatric Pulmonology 2(5); 287-291: 1986.
  15. Yuksel B, Greenough A. Variable response to bronchodilator therapy in young children born prematurely. Respiratory Medicine 87(5) :359-364; 1993.
  16. Wilkie RA, Bryan MH. Effect of bronchodilators on airway resistance in ventilator-dependant neonates with chronic lung disease. Journal of Pediatrics 111(2): 278-82; 1987.
  17. Hyde I, English RE, Williams JD. The changing pattern of chronic lung disease of prematurity. Archives of Disease in Childhood 64(4): 448-451; 1989.
  18. Stocks J, Beardsmore C, Helm P. Standardization of Lung Function tests in Paediatrics Infant Lung Function: Measurement conditions and equipment. The European Respiratory Journal-Supplement 4: 123S-129S; 1989.
  19. Asher MI, Coates AL, Collinge JM. Measurement of pleural pressure in neonates. Journal of Applied Physiology: Respiratory Environmental and Exercise Physiology 52(2): 491-494; 1982.
  20. Anonymous. American Academy of Pediatrics Committee on Drugs, American Academy of Pediatrics Committee on Environmental Health. Use of chloral hydrate for sedation in children. Pediatrics 92(3): 471-472; 1993.
  21. Grimby G, Goldman M, Mead J. Respiratory muscle action inferred from rib cage and abdominal V-P partitioning. Journal of Applied Physiology 41(5): 739-751; 1976.
  22. Coates AL, Vallinis P, Mullahoo K et al. Pulmonary Impedance as an Index of Severity and Mechanism of Neonatal Lung Disease. Pediatric Pulmonology 17(1): 41-49; 1994.
  23. Otis AB, Fenn WO, Rahn H. The Mechanics of Breathing in Man. Journal of Applied Physiology 2(3): 592-607; 1950.
  24. Zimmerman JJ. Bronchoalveolar imflammatory pathophysiology in bronchopulmonary dysplasia. Clinics in Perinatology 22(2): 429-456; 1995.
  25. Rotschild A, Solimano A, Puterman M, et al. Increased compliance in response to salbutamol in premature infants with developing bronchopulmonary dysplasia. Journal of Pediatrics 115(6): 984-991; 1989.
  26. Kirpalani H, Koren G, Schmidt B, et al. Respiratory response and pharmacokinetics of intravenous salbutamol in infants with bronchopulmonary dysplasia. Critical Care Medicine 18(12): 1374-1377; 1990.
  27. O'Callaghan C, Milner AD, Swarbrick A. Paradoxical deterioration in lung function after nebulized salbutamol in wheezing infants. Lancet 2(8521-8522): 1424-1425; 1986.
  28. Sosulski R, Abbassi S, Bhutani V, et al. Physiologic Effects of Terbutaline on Pulmonary Function of Infants with Bronchopulmonary Dysplasia. Pediatric Pulmonology 2(5): 269-273; 1986.
  29. Gorenflo M, Vogel M, Herbst L, et al. Influence of Clinical and Ventilatory Parameters on Morphology of Bronchopulmonary Dysplasia. Pediatric Pulmonology 19(4): 214-220; 1995.

Metrics

Metrics Loading ...